Cardiovascular disease assessment in rheumatoid arthritis: A guide to translating knowledge of cardiovascular risk into clinical practice

Anne Grete Semb, Silvia Rollefstad, Piet Van Riel, George D. Kitas, Eric Lawrence Matteson, Sherine E. Gabriel

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

As physicians we like to have evidence for making decisions about interventions to improve health. The evidence vacuum in the field of cardiovascular disease (CVD) prevention and clinical outcome in patients with rheumatoid arthritis (RA) has received vigorous attention in the recent literature. There is broad agreement that a patient with RA fulfilling the criteria established for the general population on CVD risk reduction should receive proven interventions, including smoking cessation, weight reduction, blood pressure control and lipidlowering therapy. In accordance with these recommendations, and despite all the uncertainties about CVD treatment threshold, targets and outcome results in RA, we firmly advocate that CVD risk should be assessed and acted on in patients with RA as recommended for the general population, even while educational CVD-preventive programmes are being developed and hard CVD end point studies are undertaken in this patient population. The initial strategies for implementing CVD risk evaluation will necessarily be modest at first. There are several possible strategies for collection of data that can be incorporated into the daily routine during rheumatology consultations at outpatient clinics. We recommend starting with these simple procedures: 1. CVD risk factor recording and evaluation using risk calculators available for the general population 2. Referral of patients with high CVD risk to a primary care physician or a cardiologist skilled in this subject for follow-up 3. Providing information about excess CVD risk and how to modify it to the patients as major stakeholders.

Original languageEnglish (US)
Pages (from-to)1284-1289
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume73
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Rheumatoid Arthritis
Cardiovascular Diseases
Population
Referral and Consultation
Preventive Health Services
Pressure control
Blood pressure
Rheumatology
Primary Care Physicians
Smoking Cessation
Risk Reduction Behavior
Vacuum
Ambulatory Care Facilities
Uncertainty
Weight Loss
Decision Making
Decision making
Health
Blood Pressure
Physicians

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Cardiovascular disease assessment in rheumatoid arthritis : A guide to translating knowledge of cardiovascular risk into clinical practice. / Semb, Anne Grete; Rollefstad, Silvia; Van Riel, Piet; Kitas, George D.; Matteson, Eric Lawrence; Gabriel, Sherine E.

In: Annals of the Rheumatic Diseases, Vol. 73, No. 7, 2014, p. 1284-1289.

Research output: Contribution to journalArticle

Semb, Anne Grete ; Rollefstad, Silvia ; Van Riel, Piet ; Kitas, George D. ; Matteson, Eric Lawrence ; Gabriel, Sherine E. / Cardiovascular disease assessment in rheumatoid arthritis : A guide to translating knowledge of cardiovascular risk into clinical practice. In: Annals of the Rheumatic Diseases. 2014 ; Vol. 73, No. 7. pp. 1284-1289.
@article{cd9c521d0cba4fdabb942fa75e0ed8af,
title = "Cardiovascular disease assessment in rheumatoid arthritis: A guide to translating knowledge of cardiovascular risk into clinical practice",
abstract = "As physicians we like to have evidence for making decisions about interventions to improve health. The evidence vacuum in the field of cardiovascular disease (CVD) prevention and clinical outcome in patients with rheumatoid arthritis (RA) has received vigorous attention in the recent literature. There is broad agreement that a patient with RA fulfilling the criteria established for the general population on CVD risk reduction should receive proven interventions, including smoking cessation, weight reduction, blood pressure control and lipidlowering therapy. In accordance with these recommendations, and despite all the uncertainties about CVD treatment threshold, targets and outcome results in RA, we firmly advocate that CVD risk should be assessed and acted on in patients with RA as recommended for the general population, even while educational CVD-preventive programmes are being developed and hard CVD end point studies are undertaken in this patient population. The initial strategies for implementing CVD risk evaluation will necessarily be modest at first. There are several possible strategies for collection of data that can be incorporated into the daily routine during rheumatology consultations at outpatient clinics. We recommend starting with these simple procedures: 1. CVD risk factor recording and evaluation using risk calculators available for the general population 2. Referral of patients with high CVD risk to a primary care physician or a cardiologist skilled in this subject for follow-up 3. Providing information about excess CVD risk and how to modify it to the patients as major stakeholders.",
author = "Semb, {Anne Grete} and Silvia Rollefstad and {Van Riel}, Piet and Kitas, {George D.} and Matteson, {Eric Lawrence} and Gabriel, {Sherine E.}",
year = "2014",
doi = "10.1136/annrheumdis-2013-204792",
language = "English (US)",
volume = "73",
pages = "1284--1289",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - Cardiovascular disease assessment in rheumatoid arthritis

T2 - A guide to translating knowledge of cardiovascular risk into clinical practice

AU - Semb, Anne Grete

AU - Rollefstad, Silvia

AU - Van Riel, Piet

AU - Kitas, George D.

AU - Matteson, Eric Lawrence

AU - Gabriel, Sherine E.

PY - 2014

Y1 - 2014

N2 - As physicians we like to have evidence for making decisions about interventions to improve health. The evidence vacuum in the field of cardiovascular disease (CVD) prevention and clinical outcome in patients with rheumatoid arthritis (RA) has received vigorous attention in the recent literature. There is broad agreement that a patient with RA fulfilling the criteria established for the general population on CVD risk reduction should receive proven interventions, including smoking cessation, weight reduction, blood pressure control and lipidlowering therapy. In accordance with these recommendations, and despite all the uncertainties about CVD treatment threshold, targets and outcome results in RA, we firmly advocate that CVD risk should be assessed and acted on in patients with RA as recommended for the general population, even while educational CVD-preventive programmes are being developed and hard CVD end point studies are undertaken in this patient population. The initial strategies for implementing CVD risk evaluation will necessarily be modest at first. There are several possible strategies for collection of data that can be incorporated into the daily routine during rheumatology consultations at outpatient clinics. We recommend starting with these simple procedures: 1. CVD risk factor recording and evaluation using risk calculators available for the general population 2. Referral of patients with high CVD risk to a primary care physician or a cardiologist skilled in this subject for follow-up 3. Providing information about excess CVD risk and how to modify it to the patients as major stakeholders.

AB - As physicians we like to have evidence for making decisions about interventions to improve health. The evidence vacuum in the field of cardiovascular disease (CVD) prevention and clinical outcome in patients with rheumatoid arthritis (RA) has received vigorous attention in the recent literature. There is broad agreement that a patient with RA fulfilling the criteria established for the general population on CVD risk reduction should receive proven interventions, including smoking cessation, weight reduction, blood pressure control and lipidlowering therapy. In accordance with these recommendations, and despite all the uncertainties about CVD treatment threshold, targets and outcome results in RA, we firmly advocate that CVD risk should be assessed and acted on in patients with RA as recommended for the general population, even while educational CVD-preventive programmes are being developed and hard CVD end point studies are undertaken in this patient population. The initial strategies for implementing CVD risk evaluation will necessarily be modest at first. There are several possible strategies for collection of data that can be incorporated into the daily routine during rheumatology consultations at outpatient clinics. We recommend starting with these simple procedures: 1. CVD risk factor recording and evaluation using risk calculators available for the general population 2. Referral of patients with high CVD risk to a primary care physician or a cardiologist skilled in this subject for follow-up 3. Providing information about excess CVD risk and how to modify it to the patients as major stakeholders.

UR - http://www.scopus.com/inward/record.url?scp=84902289738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902289738&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2013-204792

DO - 10.1136/annrheumdis-2013-204792

M3 - Article

C2 - 24608403

AN - SCOPUS:84902289738

VL - 73

SP - 1284

EP - 1289

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 7

ER -